Other markers in blood and urine, such as C-reactive protein and HDL cholesterol, are also used to assess disease activity and response to treatment in RA patients [26,27], further underlining the importance of choosing these biomarkers for study. This evidence concerns the gene CRP and rheumatoid arthritis.